

BUYER:

**AKORN INC.** 

SECTOR:

**PHARMACEUTICALS** 

Akorn, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets generic and branded prescription pharmaceuticals including ophthalmics, injectables, oral liquids, topicals, inhalants, and nasal sprays. Akorn markets its products to pharmacies, physicians, hospitals, and government agencies.

## **RED FLAGS**



Issues raised regarding production, quality control, and drug testing practices, which led to the dissolution of a proposed merger and an investigation and a warning by the FDA



Declining revenues



Operating & net losses



Insufficient liquidity with restrictive debt covenants



Inadequate cash flow

## **FINAL STRAW**


The company continued to report declining operating results. There were significant concerns around their quality control procedures, which led to the dissolution of the proposed merger. Ultimately they defaulted on their loan agreement, forcing the company into bankruptcy.

## CONCLUSIONS

Weak operating results and the debt structure were early red flags, leading to reductions in coverage in the months leading up to eventual bankruptcy. Euler Hermes took action when the proposed acquisition was dissolved and continued to see deteriorating operating results. A full risk withdrawal was recommended almost a year before the bankruptcy, helping our customers exit well ahead of the bankruptcy and avoid loss.

Akorn has secured some debtor in possession financing and is resuming operations. Akorn's ownership has been taken over by the debt holders and they are looking for a buyer while in bankruptcy.

## **RISK RATING**



Last updated September 2020

